Electrical Engineer Co-op

Chemours has launched two new refrigerants, Opteon ZE and Opteon 515B, targeting chiller applications in data centres, commercial buildings, and other critical environments. The products expand the company's low-global warming potential refrigerant portfolio as demand for AI and cloud computing infrastructure drives increased cooling requirements. Opteon ZE features an ultra-low GWP of approximately 1 and zero ozone depletion potential, whilst Opteon 515B offers a GWP of approximately 293. Both refrigerants are designed to support efficient heat removal and scalability in high-performance cooling systems. The products are currently available in strategic countries, with broader market availability planned based on demand. Chemours positions itself to manufacture and supply these refrigerants through its fluorochemicals expertise and intellectual property portfolio.

Chemours (NYSE:CC) shares gap down after earnings miss. August 5, 2026 Key points. * Chemours shares fell sharply after second-quarter adjusted EPS came in at $0.42 versus the $0.50 analyst consensus, while revenue of $1.59 billion also missed expectations of $1.65 billion. Revenue declined roughly 1.5% year over year. * Litigation expenses and lower adjusted EBITDA weighed on results, although the company generated $158 million in operating cash flow and cited data-center demand as a growth opportunity. Chemours maintained its full-year outlook for 1%-5% sales growth and $775 million-$825 million in adjusted EBITDA. * The board declared a quarterly dividend of $0.0875 per share, or $0.35 annualized, representing an indicated yield of about 2.3%; shares of record on August 14 are scheduled to be paid on September 15. * Five stocks we like better than Chemours. The Chemours Company (NYSE:CC - Get Free Report) gapped down before the market opened on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $17.93, but opened at $16.01. Chemours shares last traded at $14.94, with a volume of 1,057,830 shares. The specialty chemicals company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.08). Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The firm had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.65 billion. During the same period in the prior year, the business posted ($2.54) EPS. The business's quarterly revenue was down 1.5% compared to the same quarter last year. Chemours dividend announcement. The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th will be paid a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Friday, August 14th. Chemours's dividend payout ratio (DPR) is currently -13.26%. Key Chemours news. Here are the key news stories impacting Chemours this week: * Positive Sentiment: Chemours reported a second-quarter adjusted profit of $0.42 per share, a significant improvement from the $2.53 per-share loss reported in the year-ago quarter. The company also generated $158 million in operating cash flow and $114 million in free cash flow. Chemours Second Quarter Results * Positive Sentiment: Titanium Technologies sales increased 1% year over year to $661 million, while management highlighted growth opportunities tied to data-center applications. Full-year expectations remain intact for 1% to 5% sales growth and adjusted EBITDA of $775 million to $825 million. Chemours Data Center Growth and Litigation * Positive Sentiment: The board declared a quarterly dividend of $0.0875 per share, payable September 15 to shareholders of record August 14. The payment represents an annualized dividend of $0.35 and an indicated yield of approximately 2%. Chemours Third Quarter Dividend * Neutral Sentiment: Third-quarter revenue guidance of $1.5 billion to $1.6 billion and full-year guidance of $5.9 billion to $6.1 billion are broadly near Wall Street expectations, offering limited new upside or downside from the outlook. * Neutral Sentiment: Recent institutional activity was mixed, with some funds adding shares while major investors including BlackRock and Fidelity reduced their positions. * Negative Sentiment: Second-quarter adjusted EPS of $0.42 and revenue of $1.59 billion missed analyst estimates of approximately $0.50 and $1.65 billion, respectively. Revenue declined about 1% year over year, and adjusted EBITDA fell to $247 million from $260 million. Chemours Misses Q2 Estimates * Negative Sentiment: Litigation expenses weighed on results and overshadowed otherwise favorable data-center demand. Chemours also carried approximately $3.9 billion of gross debt at quarter-end, keeping leverage and legal liabilities as important risks for investors. Analyst ratings changes. A number of equities analysts recently weighed in on the stock. Morgan Stanley boosted their price objective on shares of Chemours from $17.00 to $21.00 and gave the stock an "equal weight" rating in a report on Monday, May 11th. Royal Bank Of Canada lifted their target price on Chemours from $26.00 to $29.00 and gave the stock an "outperform" rating in a report on Monday, May 11th. Alembic Global Advisors reaffirmed an "overweight" rating and set a $30.00 price target on shares of Chemours in a report on Wednesday, May 13th. JPMorgan Chase & Co. increased their price objective on Chemours from $17.00 to $22.00 and gave the company a "neutral" rating in a research report on Thursday, May 21st. Finally, Mizuho set a $22.00 price objective on Chemours in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Chemours has a consensus rating of "Moderate Buy" and a consensus target price of $23.80. Discover more AI Stocks Report ETF Screener Tool Institutional inflows and outflows. A number of hedge funds have recently made changes to their positions in the stock. Baird Financial Group Inc. purchased a new stake in Chemours during the 1st quarter valued at approximately $148,000. Royal Bank of Canada boosted its position in shares of Chemours by 6.8% during the first quarter. Royal Bank of Canada now owns 585,702 shares of the specialty chemicals company's stock worth $7,926,000 after acquiring an additional 37,382 shares during the last quarter. AQR Capital Management LLC bought a new position in shares of Chemours during the first quarter worth $161,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Chemours by 149.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,243 shares of the specialty chemicals company's stock valued at $593,000 after acquiring an additional 25,899 shares in the last quarter. Finally, Empowered Funds LLC purchased a new position in Chemours during the first quarter valued at $403,000. 76.26% of the stock is currently owned by institutional investors. Chemours stock performance. The company has a market capitalization of $2.27 billion, a P/E ratio of -5.71 and a beta of 1.43. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.87 and a current ratio of 1.82. The business's fifty day simple moving average is $19.67 and its 200-day simple moving average is $20.06. Chemours Company profile. Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation. Chemours' principal business activities are organized into three core segments. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Chemours, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list. While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Chemours, EPA 'behind our backs' deal heavily criticized in North Carolina. (The Center Square) - Two elected executive officers for North Carolina, and a member of the Stein administration, oppose the proposed settlement negotiated they say "behind our backs" by the EPA and Chemours. First-term Democratic Gov. Josh Stein, first-term Democratic Attorney General Jeff Jackson and Secretary Reid Wilson of the Division of Environmental Quality made their case to the U.S. assistant attorney general's office. Penalties for Wilmington, Del.-headquartered Chemours in the $450 million settlement are $22.5 million in civil penalties and implementation of injunctive relief programs. Additionally, Chemours will conduct a multi-year, $90 million program to mitigate PFAS discharges; install PFAS pollution controls for surface water discharges and air emissions at its facility in West Virginia, at an estimated cost of $60 million; supply clean drinking water for more than a decade to communities that surround its facilities in West Virginia and New Jersey at an estimated cost of $280 million; and evaluate options and implement corresponding controls to reduce releases of PFAS and other toxic chemicals from its facility in North Carolina. "Chemours and the EPA negotiated this deal behind our backs," Jackson said. "It does nothing to fix the decades of damage Chemours has done to our state, and it's offensive to the people who drink this water. That's why I'm asking the federal government to throw it out. The people of eastern North Carolina deserve better." The U.S. Department of Justice, Environmental Protection Agency, and West Virginia Department of Environmental Protection announced the deal June 24. The litigation concerns forever chemicals known as PFAS. PFAS, an acronym for per- and polyfluoroalkyl substances, are widely used, long-lasting chemicals whose components break down very slowly over time. Studies vary on their harmful effects; more is known about their impact on animals than on humans. PFAS, the Environmental Protection Agency says, "are found in water, air, fish, and soil at locations across the nation" and throughout the world. Chemours has a 6.7% market share in the global chemical sector, with $1.6 billion in liquidity per the U.S. Securities and Exchange Commission. Net sales in fiscal year 2025 were $5.8 billion, and standard earnings before interest, taxes, depreciation, and amortization - EBITDA - was $742 million. DuPont previously was the parent company of Chemours. "For decades, Chemours knowingly contaminated North Carolina's air and water by discharging PFAS from its Fayetteville plant into the Cape Fear River," Stein said. "Now, the EPA is cutting a deal with Chemours that does next to nothing for North Carolinians and allows polluters to choose what to clean up and where. I will continue to fight for North Carolinians' clean air and clean water." The trio of letter-writers say the deal should be withdrawn because EPA guidelines call for the state to be included in negotiations; the state received no drinking water relief; none of the $90 million for PFAS pollution reduction and alternative drinking water projects is required to be in North Carolina; and the state Department of Environmental Quality's demand Chemours install technology to reduce certain GenX pollution at 99.99% efficiency is greater than the EPA's 99.5% requirement, and those reductions can be claimed in other states and are not guaranteed to happen in North Carolina. They also say 200 or more Clean Water Act violations at Fayetteville Works are resolved "for no real benefit to North Carolina." The settlement addressed complaints linked to the federal Clean Water Act, Resource Conservation and Recovery Act, and Toxic Substance Control Act, along with West Virginia's Water Pollution Control Act. Chemours can "continue manufacturing PFAS for critical commercial and military applications while preventing future contamination and protecting communities from that contamination," a release from the Justice Department says. The complaint says Chemours discharged PFAS into the Ohio River, Cape Fear River and Delaware River in violation of government permits. Chemours also was accused of noncompliance with legal requirements under the Toxic Substances Control Act at all four targeted facilities. The North Carolina Supreme Court will hear oral arguments in September in Jackson's separate lawsuit against DuPont and Chemours. The StarNews newspaper in Wilmington was first to report contamination found in the Cape Fear River by N.C. State researchers in June 2017. It led to multiple litigations, the building of a $100 million thermal oxidizer designed to reduce air emissions at the riverside plant, testing, hearings and lots of finger-pointing for blame. At the time of discovery, the impact of GenX - a PFAS used to make nonstick coatings, for example, on cookware - and other PFAS on humans was evolving. Animal tests had indicated cancer possibilities, and humans were believed to be at risk for kidney or testicular cancer, elevated cholesterol levels and health challenges for children. Downstream from Chemours at the Fayetteville Works Plant, the Cape Fear River is a source of drinking water for about 1 million people in the region of a state with a population of 10.8 million. Locations. Currently in Dothan Rain Shower